Who are Floseal hemostatic matrix's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bioseal Fibrin Sealant, Blood Stopper (Ankaferd), Lipiodol Ultra Fluid with surgical glues, Pathogen-Reduced Cryoprecipitate, Haemostatic solution "Haemoblock" application, Patients receive microporous polysaccharide hemospheres..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/floseal-hemostatic-matrix.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Floseal hemostatic matrix — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Floseal hemostatic matrix (Floseal hemostatic matrix) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hemostatic agent. Area: Hemostasis / Surgical bleeding control.

marketed Hemostatic agent Thrombin-mediated fibrin formation Hemostasis / Surgical bleeding control Small molecule Live · refreshed every 30 min

Target snapshot

Floseal hemostatic matrix (Floseal hemostatic matrix) — Chang Gung Memorial Hospital. FloSeal is a hemostatic matrix that combines gelatin and thrombin to form a biologically active scaffold that promotes rapid clot formation and hemostasis at surgical bleeding sites.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Floseal hemostatic matrix TARGET	Floseal hemostatic matrix	Chang Gung Memorial Hospital	marketed	Hemostatic agent	Thrombin-mediated fibrin formation
Bioseal Fibrin Sealant	Bioseal Fibrin Sealant	Ethicon, Inc.	marketed	Fibrin sealant / Hemostatic agent
Blood Stopper (Ankaferd)	Blood Stopper (Ankaferd)	Ankara Ataturk Sanatorium Training and Research Hospital	marketed	Topical hemostatic agent
Lipiodol Ultra Fluid with surgical glues	Lipiodol Ultra Fluid with surgical glues	Guerbet	marketed	Radiographic contrast agent / Hemostatic agent
Pathogen-Reduced Cryoprecipitate	Pathogen-Reduced Cryoprecipitate	Weill Medical College of Cornell University	marketed	Blood product / Hemostatic agent
Haemostatic solution "Haemoblock" application	Haemostatic solution "Haemoblock" application	Ryazan State Medical University	marketed	Topical hemostatic agent
Patients receive microporous polysaccharide hemospheres.	Patients receive microporous polysaccharide hemospheres.	Fundación para la Investigación del Hospital Clínico de Valencia	marketed	Topical hemostatic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Floseal hemostatic matrix — Competitive Intelligence Brief. https://druglandscape.com/ci/floseal-hemostatic-matrix. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing